NeuroPace reports Q4 2022 preliminary revenue $12.8M (+16% YoY); appoints Dr. Uri Geiger to board

NeuroPace Inc

2022-FY EPS reported -$1.91 revenue$45,520,000

Q4 2022 total revenue expected ~$12.8M, up 16% from $11.0M in Q4 2021; initial implant revenue $9.8M (+15%).
Full-year 2022 revenue expected ~$45.5M, flat vs $45.2M in 2021; initial implant revenue $35.7M (+6%).
Dr. Uri Geiger, founder of Accelmed Partners, appointed to Board effective Jan 5, 2023; granted option for 120,521 shares at $1.535.
Replacement implant revenue declined 44% in Q4 ($1.4M) and 29% for FY2022 ($8.2M); DIXI Medical contributed $1.6M.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Uri Geiger

Director

NPCE · NeuroPace Inc

Effective: 2023-01-05
Filed: January 9, 2023, 6:59 PM ET

On January 4, 2023, the NeuroPace Board appointed Dr. Uri Geiger as a Class III director, effective as of January 5, 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NeuroPace Inc reported fiscal quarter and year ended December 31, 2022 results: revenue approximately $12.8 million.

Period: fiscal quarter and year ended December 31, 2022
Revenue: approximately $12.8 million
Result: preliminary results

Exact text from the filing

December 31, 2022 and the appointment of Dr. Uri Geiger to its Board of Directors. Preliminary Unaudited Fourth Quarter 2022 • Total revenue is expected to be approximately $12.8 million, representing growth of 16% compared to $11.0 million in the fourth quarter of 2021. • Initial implant revenue is expected to be approximately $9.8 million, representing growth

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Uri Geiger was appointed as Director at NeuroPace Inc.

Action: appointed
Role: Director

Exact text from the filing

On January 4, 2023, the NeuroPace Board appointed Dr. Uri Geiger as a Class III director, effective as of January 5, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

NeuroPace Inc filing history →

Source: SEC EDGAR

accession 0001193125-23-004750

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.